A breast cancer vaccine can now be tested in human trials after its investigational new drug application was accepted by the U.S. Food and Drug Administration (FDA). A Phase 1 clinical trial is expected to test the vaccine, developed by Anixa Biosciences and the Cleveland Clinic, for triple-negative breast cancer (TNBC). “We are pleased that the FDA has authorized us to commence human clinical trials of our potentially paradigm-shifting vaccine for the prevention of breast…
You must be logged in to read/download the full post.
The post Breast Cancer Vaccine Cleared by FDA for Human Testing appeared first on BioNewsFeeds.